Your browser doesn't support javascript.
loading
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L; Khan, Tahsin M; Gainor, Justin F; Iafrate, A John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A; Shaw, Alice T.
Afiliação
  • Katayama R; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Friboulet L; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Koike S; Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Lockerman EL; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Khan TM; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.
  • Gainor JF; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Iafrate AJ; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Takeuchi K; Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Taiji M; Processor Research Team, RIKEN Advanced Institute of Computational Sciences 6F, Kobe, Hyogo, Japan.
  • Okuno Y; Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Fujita N; Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. naoya.fujita@jfcr.or.jp jengelman@mgh.harvard.edu ashaw1@mgh.harvard.edu.
  • Engelman JA; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. naoya.fujita@jfcr.or.jp jengelman@mgh.harvard.edu ashaw1@mgh.harvard.edu.
  • Shaw AT; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. naoya.fujita@jfcr.or.jp jengelman@mgh.harvard.edu ashaw1@mgh.harvard.edu.
Clin Cancer Res ; 20(22): 5686-96, 2014 Nov 15.
Article em En | MEDLINE | ID: mdl-25228534
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Carbazóis / Receptores Proteína Tirosina Quinases / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Mutação Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Carbazóis / Receptores Proteína Tirosina Quinases / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Mutação Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Japão